ArticleInternational journal of clinical and experimental pathology2015
Cancer burden in China from 2006 to 2010.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004-2020.BMC cancer · 2024Article
- Serological TK1 predict pre-cancer in routine health screenings of 56,178 people.Cancer biomarkers : section A of Disease markers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the incidence, mortality, and disease burden of cancer in China to provide a reference for cancer prevention and control.
methodsCancer registry data (2006-2010) were collected from the Chinese Cancer Registry Annual Report by the National Center for Cancer Registries. Cancer incidence and mortality, potential years of life lost (PYLL), and disability-adjusted life years (DALYs) were calculated.
resultsThe cancer incidence rate was 267.13/100,000 overall, 299.13/100,000 in men, and 234.06/100,000 in women (1.2 times higher in men than in women). The cancer mortality rate was 176.32/100,000 overall, 220.54/100,000 in men, and 130.60/100,000 in women (1.6 times higher in men than in women). The incidence rate was higher in urban areas (285.97/100,000) than in rural areas (250.91/100,000), whereas the mortality rate was higher in rural areas (179.25/100,000) than in urban areas (172.91/100,000). The rural: urban incidence ratio decreased from 0.89 in 2006 to 0.69 in 2010, and the rural: urban mortality ratio decreased from 1.10 to 0.91 in the same years. PYLL rates and DALY rates were higher in men (16.45 and 22.19, respectively) than in women (11.22 and 13.87, respectively) and in rural areas (17.6 and 22.17, respectively) than in urban areas (12.6 and 17.09, respectively). The male: female ratios for PYLL and DALY rates were 1.46 and 1.6, respectively. The rural: urban ratios for PYLL and DALY rates decreased from 1.63 in 2006 to 1.22 in 2010 and from 1.51 in 2006 to 1.08 in 2010, respectively.
conclusionThe disease burden of cancer in China in 2006-2010 was substantial, particularly for men and residents of rural districts.
Indexed as
Identifiers
26722536PMC4680481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.